Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis

Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …

Find out details on these three critical Nvidia partners immediately.

Amirali Talasaz Biography and Net Worth

COO of Guardant Health

AmirAli Talasaz, Ph.D. is the co-founder of Guardant Health and has served as the Co-Chief Executive Officer since August 2021. Prior to founding Guardant, Dr. Talasaz held various positions at Illumina, including Senior Director of Diagnostics Research from October 2011 to June 2012, where he led the efforts for emerging clinical applications of next-generation genomic analysis. During that time, he developed different genomic technologies suitable for clinical applications. In March 2008, he founded Auriphex Biosciences, Inc., which focused on purification and genetic analysis of circulating tumor cells for cancer management. The technology was acquired by lllumina in 2009. During his academic years, he led the Technology Development group at SGTC. He received his Ph.D. degree in electrical engineering, M.S. degree in electrical engineering and M.S. degree in management science and engineering from Stanford University.

What is Amirali Talasaz's net worth?: The estimated net worth of Amirali Talasaz is at least $59.98 million as of March 13th, 2023. Dr. Talasaz owns 1,893,845 shares of Guardant Health stock worth more than $59,978,071 as of December 21st. This net worth estimate does not reflect any other investments that Dr. Talasaz may own. Learn More about Amirali Talasaz's net worth.
How do I contact Amirali Talasaz?: The corporate mailing address for Dr. Talasaz and other Guardant Health executives is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. Guardant Health can also be reached via phone at (855) 698-8887 and via email at [email protected]. Learn More on Amirali Talasaz's contact information.
Has Amirali Talasaz been buying or selling shares of Guardant Health?: Amirali Talasaz has not been actively trading shares of Guardant Health in the last ninety days. Most recently, on Monday, March 13th, Amirali Talasaz bought 40,000 shares of Guardant Health stock. The stock was acquired at an average cost of $25.66 per share, with a total value of $1,026,400.00. Following the completion of the transaction, the chief executive officer now directly owns 1,893,845 shares of the company's stock, valued at $48,596,062.70. Learn More on Amirali Talasaz's trading history.
Who are Guardant Health's active insiders?: Guardant Health's insider roster includes Derek Bertocci (CFO), Ian Clark (Director), Helmy Eltoukhy (CEO), Meghan Joyce (Director), Kumud Kalia (Insider), Samir Kaul (Director), Stanley Meresman (Director), Amelia Merrill (SVP), and Amirali Talasaz (COO). Learn More on Guardant Health's active insiders.
Are insiders buying or selling shares of Guardant Health?: During the last year, Guardant Health insiders bought shares 1 times. They purchased a total of 2,187 shares worth more than $38,972.34. During the last year, insiders at the sold shares 6 times. They sold a total of 5,632 shares worth more than $180,115.00. The most recent insider tranaction occured on December, 18th when Director Musa Tariq sold 116 shares worth more than $4,042.60. Insiders at Guardant Health own 5.5% of the company. Learn More about insider trades at Guardant Health.
Information on this page was last updated on 12/18/2024.

Amirali Talasaz Insider Trading History at Guardant Health

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/13/2023	Buy	40,000	$25.66	$1,026,400.00	1,893,845
2/11/2021	Sell	6,613	$168.46	$1,114,025.98
2/8/2021	Sell	92,708	$162.39	$15,054,852.12	2,380,745
2/5/2021	Sell	201,861	$161.76	$32,653,035.36	2,380,745
2/3/2021	Sell	76,915	$158.72	$12,207,948.80	2,530,280
2/1/2021	Sell	95,744	$154.41	$14,783,831.04	2,844,187
10/26/2020	Sell	4,613	$105.02	$484,457.26	2,539,532
10/23/2020	Sell	13,136	$105.15	$1,381,250.40	2,539,532
10/16/2020	Sell	23,400	$102.44	$2,397,096.00	2,539,532
9/25/2020	Sell	75,000	$110.71	$8,303,250.00	2,570,412
9/2/2020	Sell	75,000	$94.15	$7,061,250.00	2,680,976
8/4/2020	Sell	15,000	$84.19	$1,262,850.00	2,749,532
7/6/2020	Sell	20,108	$84.10	$1,691,082.80	2,744,424
7/2/2020	Sell	54,892	$83.87	$4,603,792.04	2,744,424
5/11/2020	Sell	199,951	$91.68	$18,331,507.68	2,981,195
5/8/2020	Sell	25,049	$90.13	$2,257,666.37	2,981,195
5/6/2020	Sell	100,000	$81.24	$8,124,000.00	3,169,387
5/4/2020	Sell	63,971	$73.22	$4,683,956.62	3,169,387
4/28/2020	Sell	13,082	$80.23	$1,049,568.86	3,211,345
4/20/2020	Sell	2,729	$72.56	$198,016.24	78,831
4/17/2020	Sell	7,771	$72.70	$564,951.70	78,831
4/2/2020	Sell	5,250	$67.03	$351,907.50	76,310
12/19/2019	Sell	62,587	$80.71	$5,051,396.77	71,951
12/17/2019	Sell	203	$80.00	$16,240.00	71,951
11/25/2019	Sell	11,390	$80.19	$913,364.10	72,371
11/20/2019	Sell	1,310	$79.34	$103,935.40	72,321
8/26/2019	Sell	618	$93.52	$57,795.36
8/23/2019	Sell	52,715	$97.63	$5,146,565.45
8/16/2019	Sell	100,000	$100.17	$10,017,000.00
4/24/2019	Sell	117,540	$66.69	$7,838,742.60
4/22/2019	Sell	232,460	$65.60	$15,249,376.00

Amirali Talasaz Buying and Selling Activity at Guardant Health

Guardant Health Company Overview

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Today's Range

Now: $31.67

$30.49

$32.22

50 Day Range

MA: $29.13

$20.20

$38.11

2 Week Range

Now: $31.67

$15.81

$38.53

Volume

2,414,304 shs

Average Volume

2,035,487 shs

Market Capitalization

$3.91 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.26